Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News



Format: 04/16/2014
Format: 04/16/2014


Reuters: US approves Novartis blood pressure combo drug

Wednesday, July 22nd, 2009

ZURICH, July 21 (Reuters) - U.S. regulators have approved Novartis AG's (NOVN.VX) Tekturna HCT combination as an initial treatment for patients who are unlikely to respond sufficiently to a single drug, the Swiss company said on Tuesday.

Tekturna HCT is a single pill combination of Novartis' Tekturna drug and one of the most widely used high blood pressure drugs, the diuretic hydrochlorothiazide.

"Up to 85 percent of patients will need more than one medication to reach their blood pressure goals," Dr. Alan Gradman, cardiologist at West Penn Hospital and Professor of Medicine at Temple University, said in a Novartis statement.

High blood pressure affects nearly one billion people around the world and is a major risk factor for cardiovascular disease, the top cause of death globally.


West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 3 + 8 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.